ViferaXS Raises €12 Million to Advance Phase II Trial in Chronic Lymphocytic Leukemia and Expand Its Oncology Pipeline

Phase 2CLLTAXS01Positive

AI Analysis

Summary

ViferaXS closed a €12 million financing round led by SPRIND and Huma to advance its Phase II trial of CLLTAXS01 in chronic lymphocytic leukemia and expand its oncology pipeline.

Clinical Trial Data

Phase

Phase II

Importance:6/10

Sentiment:

0.70

financingoncologyPhase 2chronic lymphocytic leukemiagrant funding

Related Companies

$DFPH

Read the original article

Published by PR Newswire Biotech on September 23, 2026 12:15 PM

Read Original